Poorly Differentiated Neuroendocrine Carcinoma of the Pancreas Responsive to Combination Therapy with Gemcitabine and S-1
-
- Yamamoto Mitsuyoshi
- The Third Department of Internal Medicine, University of Occupational and Environmental Health, School of Medicine, Japan
-
- Miyagawa Koichiro
- The Third Department of Internal Medicine, University of Occupational and Environmental Health, School of Medicine, Japan
-
- Hiura Masaaki
- The Third Department of Internal Medicine, University of Occupational and Environmental Health, School of Medicine, Japan
-
- Taguchi Masashi
- The Third Department of Internal Medicine, University of Occupational and Environmental Health, School of Medicine, Japan
-
- Kihara Yasuyuki
- The Third Department of Internal Medicine, University of Occupational and Environmental Health, School of Medicine, Japan
-
- Abe Shintaro
- The Third Department of Internal Medicine, University of Occupational and Environmental Health, School of Medicine, Japan
-
- Shimajiri Shohei
- Department of Pathology and Cell Biology, University of Occupational and Environmental Health, School of Medicine, Japan
-
- Harada Masaru
- The Third Department of Internal Medicine, University of Occupational and Environmental Health, School of Medicine, Japan
この論文をさがす
抄録
Poorly differentiated neuroendocrine carcinoma is a very rare malignancy, but it is characterized by agressive histological features and a poor clinical prognosis. We report a 42-year-old man who had poorly differentiated neuroendocrine carcinoma of the pancreas with multiple liver metastases. We administrated combined chemotherapy with S-1 and gemcitabine. This treatment was efficacious and well tolerated, and then this patient obtained objective partial response for 7 months and survived for 13 months after the diagnosis. This case suggests that S-1 and gemcitabine combination produce beneficial responses for patients with this disease.<br>
収録刊行物
-
- Internal Medicine
-
Internal Medicine 51 (7), 727-732, 2012
一般社団法人 日本内科学会